In this regard Novo Nordisk is leading the way. We've become increasingly committed to chronic conditions that include cardiovascular disease and chronic kidney disease – the reason being ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn't match the effects seen with the injectable ...

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

A spirited pro/con debate at ERA 2025 explores whether population-level albuminuria screening could improve early CKD ...

EXCLUSIVE: The dialysis company believes the impact of the treatments on its own performance will be ‘neutral to positive’ ...

An international clinical trial, led in the UK by Swansea’s Joint Clinical Research Facility (JCRF), has found that ...

With many different species entering torpor for a variety of reasons, scientists are looking to their sleepy secrets for ways ...

Discover six kidney disease companies actively working on innovative treatments that could make a difference to patients' lives.

Management of older adults with type 2 diabetes and chronic kidney disease is complex. These individuals often have multiple comorbidities, take several medications, and are at increased risk of ...